author-photo

Skl Chia

9

Papers

26

Citations

Citation Trend

Filter By

Papers (7) Sort By

Journal Conference Others

Abstract P2-13-01: Efficacy of neratinib in hormone receptor-positive patients who initiated treatment within 1 year of completing trastuzumab-based adjuvant therapy in HER2+ early-stage breast cancer: Subgroup analyses from the phase III ExteNET trial

2019 Cancer Research
Show All
- Source
- Cite
- Save
Citations (2)
Abstract P1-13-03: Effects of neratinib after trastuzumab-based adjuvant therapy in hormone receptor-positive HER2+ early-stage breast cancer: Exploratory analyses from the phase III ExteNET trial

2018 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Abstract PD5-12: Buparlisib (BUP) or placebo (PBO) plus fulvestrant (FUL) in postmenopausal patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC): Overall survival (OS) results from BELLE-2, a randomized, phase III study

2018 Cancer Research
Show All
- Source
- Cite
- Save
Citations (1)
149ONeratinib after trastuzumab (T)-based adjuvant therapy in early-stage HER2+ breast cancer (BC): 5-year analysis of the phase III ExteNET trial

2017 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (5)
323TiPEarLEE-1: A phase 3 study of ribociclib + endocrine therapy (ET) for adjuvant treatment of patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–), high-risk, early breast cancer (EBC)

2017 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (3)
Abstract S5-02: Neratinib after trastuzumab-based adjuvant therapy in early-stage HER2+ breast cancer: 3-year analysis from a phase 3 randomized, placebo-controlled, double-blind trial (ExteNET)

2016 Cancer Research
Show All
- Source
- Cite
- Save
Citations (9)
A phase III trial of adjuvant neratinib (NER) after trastuzumab (TRAS) in women with early-stage HER2+ breast cancer (BC).

2011 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (4)